These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

206 related articles for article (PubMed ID: 38597742)

  • 1. Cost-effectiveness analysis 3L of axicabtagene ciloleucel vs tisagenlecleucel and lisocabtagene maraleucel in Japan.
    Tsutsué S; Makita S; Asou H; Matsuda H; Yamaura R; Taylor TD
    Future Oncol; 2024; 20(19):1333-1349. PubMed ID: 38597742
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A Cost-Effectiveness Analysis of Axicabtagene Ciloleucel versus Tisagenlecleucel in the Treatment of Diffuse Large B-cell Lymphoma Based on a Real-World French Registry.
    Ray M; Castaigne JG; Zang A; Patel A; Hancock E; Brighton N; Bachy E
    Adv Ther; 2024 Nov; 41(11):4282-4298. PubMed ID: 39316290
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Cost-effectiveness of axicabtagene ciloleucel versus lisocabtagene maraleucel for adult patients with relapsed or refractory large B-cell lymphoma after two or more lines of systemic therapy in the US.
    Oluwole OO; Liu R; Diakite I; Feng C; Patel A; Nourhussein I; Snider JT; Locke FL
    J Med Econ; 2022; 25(1):541-551. PubMed ID: 35443867
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Cost-Effectiveness of Lisocabtagene Maraleucel Versus Axicabtagene Ciloleucel and Tisagenlecleucel in the Third-Line or Later Treatment Setting for Relapsed or Refractory Large B-cell Lymphoma in the United States.
    Parker C; Liu FF; Deger KA; Franco-Villalobos C; Proskorovsky I; Keating SJ; Sorensen S
    Adv Ther; 2023 May; 40(5):2355-2374. PubMed ID: 36947328
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Cost-Effectiveness of Chimeric Antigen Receptor T Cell Therapy in Patients with Relapsed or Refractory Large B Cell Lymphoma: No Impact of Site of Care.
    Cummings Joyner AK; Snider JT; Wade SW; Wang ST; Buessing MG; Johnson S; Gergis U
    Adv Ther; 2022 Aug; 39(8):3560-3577. PubMed ID: 35689726
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Cost-effectiveness of axicabtagene ciloleucel versus tisagenlecleucel for the treatment of 3L + relapsed/refractory large B-cell lymphoma in the United States: incorporating longer survival results.
    Oluwole OO; Ray MD; Davies N; Bradford R; Jones C; Patel AR; Locke FL
    J Med Econ; 2024; 27(1):230-239. PubMed ID: 38240256
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Cost effectiveness of axicabtagene ciloleucel versus tisagenlecleucel for adult patients with relapsed or refractory large B-cell lymphoma after two or more lines of systemic therapy in the United States.
    Liu R; Oluwole OO; Diakite I; Botteman MF; Snider JT; Locke FL
    J Med Econ; 2021; 24(1):458-468. PubMed ID: 33691581
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Network meta-analysis of CAR T-Cell therapy for the treatment of 3L+ R/R LBCL after using published comparative studies.
    Oluwole OO; Neelapu SS; Ray MD; Limbrick-Oldfield EH; Wade SW; Kanters S; Patel AR; Locke FL
    Expert Rev Anticancer Ther; 2024 Jun; 24(6):457-465. PubMed ID: 38646700
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Axicabtagene Ciloleucel versus Tisagenlecleucel for Relapsed or Refractory Large B Cell Lymphoma: A Systematic Review and Meta-Analysis.
    Gagelmann N; Bishop M; Ayuk F; Bethge W; Glass B; Sureda A; Pasquini MC; Kröger N
    Transplant Cell Ther; 2024 Jun; 30(6):584.e1-584.e13. PubMed ID: 38281590
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Matching-adjusted indirect treatment comparison of liso-cel versus axi-cel in relapsed or refractory large B cell lymphoma.
    Maloney DG; Kuruvilla J; Liu FF; Kostic A; Kim Y; Bonner A; Zhang Y; Fox CP; Cartron G
    J Hematol Oncol; 2021 Sep; 14(1):140. PubMed ID: 34493319
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Cost-effectiveness of treating relapsed or refractory 3L+ follicular lymphoma with axicabtagene ciloleucel vs mosunetuzumab in the United States.
    Oluwole OO; Ray MD; Zur RM; Ferrufino CP; Doble B; Patel AR; Bilir SP
    Front Immunol; 2024; 15():1393939. PubMed ID: 38855109
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Matching-adjusted indirect comparison of axi-cel and liso-cel in relapsed or refractory large B-cell lymphoma.
    Oluwole OO; Chen JMH; Chan K; Patel AR; Jansen JP; Keeping S; Zheng Y; Snider JT; Locke FL
    Leuk Lymphoma; 2022 Dec; 63(13):3052-3062. PubMed ID: 36048026
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Comparative efficacy of tisagenlecleucel and lisocabtagene maraleucel among adults with relapsed/refractory large B-cell lymphomas: an indirect treatment comparison.
    Schuster SJ; Zhang J; Yang H; Agarwal A; Tang W; Martinez-Prieto M; Bollu V; Kuzan D; Maziarz RT; Kersten MJ
    Leuk Lymphoma; 2022 Apr; 63(4):845-854. PubMed ID: 34978255
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A Review of Two Regulatory Approved Anti-CD19 CAR T-Cell Therapies in Diffuse Large B-Cell Lymphoma: Why Are Indirect Treatment Comparisons Not Feasible?
    Zhang J; Li J; Ma Q; Yang H; Signorovitch J; Wu E
    Adv Ther; 2020 Jul; 37(7):3040-3058. PubMed ID: 32524498
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Cost-Effectiveness Analysis of Axicabtagene Ciloleucel vs. Tisagenlecleucel for the Management of Relapsed/Refractory Diffuse Large B-Cell Lymphoma in Spain.
    Bastos-Oreiro M; de Las Heras A; Presa M; Casado MA; Pardo C; Martín-Escudero V; Sureda A
    Cancers (Basel); 2022 Jan; 14(3):. PubMed ID: 35158805
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Cost Effectiveness of Chimeric Antigen Receptor T-Cell Therapy in Multiply Relapsed or Refractory Adult Large B-Cell Lymphoma.
    Lin JK; Muffly LS; Spinner MA; Barnes JI; Owens DK; Goldhaber-Fiebert JD
    J Clin Oncol; 2019 Aug; 37(24):2105-2119. PubMed ID: 31157579
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Value for Money of CAR-T Cell Therapy for Patients with Diffuse Large B-cell Lymphoma in China: Evidence from a Cost-Effectiveness Analysis.
    Wu W; Zhou Y; Wang Y; Keramat SA; Balasooriya NN; Zhao Z; Yang Y; Comans T; Dong H
    Appl Health Econ Health Policy; 2023 Sep; 21(5):773-783. PubMed ID: 37356080
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Cost-effectiveness analysis of transplant-ineligible relapsed or refractory diffuse large B-cell lymphoma treatment options-Experience of the efficiency frontier approach.
    Kurte MS; Siefen AC; Jakobs F; von Tresckow B; Reinhardt HC; Kron F
    Eur J Haematol; 2023 Dec; 111(6):895-908. PubMed ID: 37644352
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A Model to Estimate Cytokine Release Syndrome and Neurological Event Management Costs Associated With CAR T-Cell Therapy.
    Badaracco J; Gitlin M; Keating SJ
    Transplant Cell Ther; 2023 Jan; 29(1):59.e1-59.e6. PubMed ID: 36272529
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Second-Line Chimeric Antigen Receptor T-Cell Therapy in Diffuse Large B-Cell Lymphoma : A Cost-Effectiveness Analysis.
    Kelkar AH; Cliff ERS; Jacobson CA; Abel GA; Dijk SW; Krijkamp EM; Redd R; Zurko JC; Hamadani M; Hunink MGM; Cutler C
    Ann Intern Med; 2023 Dec; 176(12):1625-1637. PubMed ID: 38048587
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.